Stuttgart
04.09.26 | 21:46
0,152 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,146 | 0,176 | 19:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | Oncopeptides Q2 2026 slides: 62% sales growth, 3rd-line expansion | 2 | Investing.com | ||
| 27.08. | Oncopeptides: Umsatz steigt im zweiten Quartal um 62 %, Aktie legt zu | 2 | Investing.com Deutsch | ||
| 27.08. | Oncopeptides AB Q2 Loss Narrows | 3 | RTTNews | ||
| 27.08. | Oncopeptides AB: Oncopeptides publishes Q2 report 2026 | 282 | GlobeNewswire (Europe) | Stockholm - August 27, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 17.08. | Oncopeptides AB: Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe | 558 | GlobeNewswire (Europe) | STOCKHOLM - August 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Public Agency of the Republic of Slovenia... ► Artikel lesen | |
| ONCOPEPTIDES Aktie jetzt für 0€ handeln | |||||
| 08.06. | Oncopeptides AB: First patient enrolled in Oncopeptides' real-world evidence study MARINA in Germany | 557 | GlobeNewswire (Europe) | STOCKHOLM - June 8, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the first patient has been enrolled in... ► Artikel lesen | |
| 26.05. | Oncopeptides AB: Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe | 397 | GlobeNewswire (Europe) | STOCKHOLM, May 26, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has entered into an agreement with SALUS,... ► Artikel lesen | |
| 21.05. | Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides | 282 | GlobeNewswire (Europe) | STOCKHOLM - May 21, 2026 - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 21 May 2026. At the Annual General Meeting, the following principal resolutions were passed.
The... ► Artikel lesen | |
| 13.05. | Oncopeptides AB Q1 Loss Drops | 6 | RTTNews | ||
| 13.05. | Oncopeptides AB: Oncopeptides publishes Q1 report 2026 | 639 | GlobeNewswire (Europe) | Stockholm - May 13, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 11.05. | Oncopeptides AB: Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment | 304 | GlobeNewswire (Europe) | STOCKHOLM - May 11, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces its intention to submit a Type II variation application... ► Artikel lesen | |
| 17.03. | Oncopeptides AB: Outcome in Oncopeptides' rights issue | 398 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| 16.03. | Oncopeptides AB: Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany | 1.120 | GlobeNewswire (Europe) | STOCKHOLM - March 16, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces the initiation of the MARINA study in close... ► Artikel lesen | |
| 09.03. | Oncopeptides AB: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma | 508 | GlobeNewswire (Europe) | Stockholm, March 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that it has achieved key regulatory agreement... ► Artikel lesen | |
| 24.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.02.2026 | 396 | Xetra Newsboard | Das Instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 24.02.2026 und ex Kapitalmassnahme am 25.02.2026 The instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY... ► Artikel lesen | |
| 19.02. | Oncopeptides AB: Oncopeptides carries out a rights issue of approximately SEK 200 million | 515 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| 19.02. | Oncopeptides AB: Oncopeptides publishes year-end report 2025 | 388 | GlobeNewswire (Europe) | Stockholm - February 19, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2025.
"Oncopeptides... ► Artikel lesen | |
| 15.01. | Oncopeptides AB: Oncopeptides announces Q4 2025 sales and updates cash-flow expectations | 441 | GlobeNewswire (Europe) | Stockholm, January 15, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the fourth quarter of 2025 and... ► Artikel lesen | |
| 05.11.25 | Oncopeptides AB: Oncopeptides publishes Q3 report 2025 | 413 | GlobeNewswire (Europe) | Stockholm - November 5, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2025.
"The third... ► Artikel lesen | |
| 17.09.25 | Oncopeptides AB: Oncopeptides' rights issue oversubscribed to approximately 157 percent | 477 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,55 | +0,22 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| EVOTEC | 3,212 | -1,89 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| MEDIGENE | 0,006 | -6,25 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| MODERNA | 125,24 | -0,03 % | Notable healthcare headlines for the week: UnitedHealth, Moderna, and Medtronic in focus | ||
| VALNEVA | 2,977 | +0,61 % | Valneva (ISIN: FR0004056851) im Fokus: Biotechnologie mit dem Hebel für die Zukunft | ||
| AMGEN | 376,90 | +0,13 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| NOVAVAX | 8,740 | -0,57 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| STRYKER | 261,30 | +0,11 % | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| BIOGEN | 189,50 | -0,34 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| BIOFRONTERA | 2,400 | -3,23 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,490 | +1,22 % | Heidelberg Pharma baut ADC-Partnerschaft mit Huadong Medicine aus | Heidelberg Pharma erweitert die Zusammenarbeit mit seinem strategischen Partner und zweitgrößten Aktionär Huadong Medicine aus China. Beide Unternehmen wollen gemeinsam neue Antikörper-Wirkstoff-Konjugate... ► Artikel lesen | |
| ILLUMINA | 187,78 | -0,04 % | S&P Dow Jones Indices: Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 | NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% |
Das Unternehmen ONCOPEPTIDES AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,152 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOPEPTIDES AB finden Sie auf Wallstreet Online.